Search clinical trials for: Rivastigmine 13.3 mg/24 h (15 cm^2)

Total 8 results

Novartis

Completed

Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44 (ACTION)

Alzheimer's Disease

United States, Puerto Rico
Luye Pharma Group Ltd.
SocraTec R&D GmbH; SocraMetrics GmbH

Completed

Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (13.3mg/24h)

Healthy

Germany
Novartis Pharmaceuticals

Completed

Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline

Alzheimer Disease

United States, Germany, Italy, Spain, France, Canada, Switzerland
SocraTec R&D GmbH
SocraMetrics GmbH

Completed

Rivastigmine BA Trial With Multiple Application of Transdermal Patches, Adaptation and Tapering Phase

Bioequivalence

Germany
SocraTec R&D GmbH

Completed

Rivastigmine Bioequivalence Trial With Multiple Applications of Transdermal Patches (9.5 mg/24 h)

Bioequivalence

Germany
UCB Biopharma SRL

Terminated

A Follow-up Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome

Restless Legs Syndrome

United States
SocraTec R&D GmbH
SocraMetrics GmbH

Completed

Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (9.5mg/24h)

Bioequivalence

Germany
Alexza Pharmaceuticals, Inc.
Atlanta Center for Medical Research

Completed

Staccato Loxapine Multidose PK

Volunteers on Chronic, Stable Antipsychotic Regimens

United States

3

Subscribe